Stereoselective synthesis and anti-proliferative effects on prostate cancer evaluation of 5-substituted-3,4-diphenylfuran-2-ones

被引:22
作者
Liu, Gai-Zhi [1 ]
Xu, Hai-Wei [2 ]
Wang, Peng [2 ]
Lin, Zong-Tao [3 ]
Duan, Ying-Chao [2 ]
Zheng, Jia-Xin [2 ]
Liu, Hong-Min [2 ]
机构
[1] Henan Univ Tradit Chinese Med, Sch Pharm, Zhengzhou 450046, Henan, Peoples R China
[2] Zhengzhou Univ, Sch Pharmaceut Sci, Zhengzhou 450001, Peoples R China
[3] Univ Tennessee, Hlth Sci Ctr, Coll Pharm, Dept Pharmaceut Sci, Memphis, TN 38163 USA
关键词
Rofecoxib; 5-Substituted-3,4-diphenylfuran-2-one; Prostate cancer; Anti-proliferative; Cell cycle arrest; ANDROGRAPHOLIDE DERIVATIVES; CYCLOOXYGENASE-2; INHIBITOR; ASPIRIN USE; ROFECOXIB; 4-(4'-METHYLSULFONYLPHENYL)-3-PHENYL-2(5H)-FURANONE; CELECOXIB; MK-0966; DESIGN; TARGET; RISK;
D O I
10.1016/j.ejmech.2013.04.062
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Series of 5-substituted-3,4-diphenylfuran-2-ones were stereoselectively prepared. Their potential anti-proliferative effects on prostate cancer and some of their cyclooxygenases (COXs) inhibitory activities were evaluated. Structure activity relationship (SAR) data, acquired by substituent modification at the para-position and ortho-position of the C-3 phenyl ring and 5-substituted modification of the central furanone, showed that 3-(2-chloro-phenyl)-4-(4-methanesulfonyl-phenyl)-5-(1-methoxy-ethyl)-5H-furan-2-one (13p) was the most potent compound and could effectively reduce the proliferation of prostate cancer cells (PC3 cell IC50 = 20 mu M; PD PCDNA cell IC50 = 5 mu M; PD SKP2 cell IC50 = 5 mu M; DU145 cell IC50 = 25 mu M). The cell cycle analysis for 13p in DU145 indicated that 13p may induce G1 phase arrest. (C) 2013 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:323 / 336
页数:14
相关论文
共 35 条
[1]  
[Anonymous], 2009, SNAPSH PROST CANC
[2]  
Attiga FA, 2000, CANCER RES, V60, P4629
[3]  
Chan CC, 1999, J PHARMACOL EXP THER, V290, P551
[4]   Studies on the novel α-glucosidase inhibitory activity and structure-activity relationships for andrographolide analogues [J].
Dai, GF ;
Xu, HW ;
Wang, JF ;
Liu, FW ;
Liu, HM .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2006, 16 (10) :2710-2713
[5]   Expression of biomarkers modulating prostate cancer progression: implications in the treatment of the disease [J].
Di Lorenzo, G ;
De Placido, S ;
Autorino, R ;
De Laurentiis, M ;
Mignogna, C ;
D'Armiento, M ;
Tortora, G ;
De Rosa, G ;
D'Armiento, M ;
De Sio, M ;
Bianco, AR ;
D'Armiento, FP .
PROSTATE CANCER AND PROSTATIC DISEASES, 2005, 8 (01) :54-59
[6]   Cyclooxygenase-2 promotes prostate cancer progression [J].
Fujita, H ;
Koshida, K ;
Keller, ET ;
Takahashi, Y ;
Yoshimito, T ;
Namiki, M ;
Mizokami, A .
PROSTATE, 2002, 53 (03) :232-240
[7]   ASPIRIN USE AND THE RISK FOR COLORECTAL-CANCER AND ADENOMA IN MALE HEALTH-PROFESSIONALS [J].
GIOVANNUCCI, E ;
RIMM, EB ;
STAMPFER, MJ ;
COLDITZ, GA ;
ASCHERIO, A ;
WILLETT, WC .
ANNALS OF INTERNAL MEDICINE, 1994, 121 (04) :241-246
[8]  
Gupta S, 2000, PROSTATE, V42, P73, DOI 10.1002/(SICI)1097-0045(20000101)42:1<73::AID-PROS9>3.0.CO
[9]  
2-G
[10]   The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2 [J].
Hsu, AL ;
Ching, TT ;
Wang, DS ;
Song, XQ ;
Rangnekar, VM ;
Chen, CS .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (15) :11397-11403